Titan Pharmaceuticals Inc... (TTNP)
NASDAQ: TTNP
· Real-Time Price · USD
4.15
0.07 (1.72%)
At close: Sep 09, 2025, 3:58 PM
4.05
-2.41%
After-hours: Sep 09, 2025, 07:23 PM EDT
Titan Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant Revenue | n/a | 4K | 82K | 98K | 406K | 91K | 353K | 569K | 951K | 1.02M | 1.2M | 1.13M | 1.02M | 757K | 198K |
| Grant Revenue Growth | -100.00% | -95.12% | -16.33% | -75.86% | +346.15% | -74.22% | -37.96% | -40.17% | -6.58% | -15.45% | +6.93% | +10.39% | +34.74% | +282.32% | n/a |
| License and Service Revenue | n/a | n/a | 1K | n/a | 56K | 4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| License and Service Revenue Growth | n/a | n/a | n/a | n/a | +1300.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 657K | 534K | 666K | 754K | 2.07M | 1.06M | 1.44M | 1.64M | 1.23M | 1.23M | 1.29M | 1.81M | 1.62M | 1.32M | 1.65M | 979K | 1.03M | 1.33M | -4.34M | 3.55M | 3.47M | 3.11M | 2.59M | 3.02M | 3.23M | 3.08M | 2.36M | 1.51M | 1.38M | 1.61M | 1.13M | 1.4M | 1.2M | 1.35M | 1.2M | 1.05M | 1.21M | 1.13M | 1.11M | 792K | 753K | 1.09M |
| Selling, General, and Administrative Revenue Growth | +23.03% | -19.82% | -11.67% | -63.65% | +95.48% | -26.37% | -12.19% | +33.52% | -0.41% | -4.27% | -28.63% | +11.62% | +22.39% | -19.78% | +68.34% | -5.41% | -22.00% | -130.60% | -222.18% | +2.16% | +11.56% | +20.28% | -14.36% | -6.44% | +4.83% | +30.70% | +55.75% | +9.71% | -14.55% | +43.56% | -19.41% | +16.62% | -11.40% | +12.68% | +13.97% | -13.34% | +7.34% | +1.43% | +40.78% | +5.18% | -31.23% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | 487K | 424K | 442K | 561K | 1.44M | 932K | 974K | 1.41M | 976K | 1.19M | 1.65M | 1.88M | 70K | 1.56M | 2.01M | 2.28M | 1.87M | 1.62M | 1.91M | 1.84M | 1.85M | 1.91M | 1.86M | 1.86M | 2.31M | 2.71M | 2.5M | 2.13M | 2.09M | 1.59M | 1.75M | 700K | 1.14M | 1.01M | 1.1M | 1.43M |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | -100.00% | +14.86% | -4.07% | -21.21% | -61.12% | +54.83% | -4.31% | -30.87% | +44.36% | -18.19% | -27.52% | -12.31% | +2581.43% | -95.52% | -22.17% | -11.86% | +21.63% | +15.63% | -15.10% | +3.42% | -0.59% | -2.88% | +2.85% | +0.05% | -19.55% | -15.00% | +8.52% | +17.64% | +1.72% | +31.45% | -8.93% | +149.43% | -38.33% | +12.38% | -8.10% | -23.20% | n/a |